We are live on ! Find out more
SLXNW

Silexion Therapeutics Warrant

31 hedge funds and large institutions have $106K invested in Silexion Therapeutics Warrant in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
31
Holders Change
+31
Holders Change %
% of All Funds
0.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
31
Increased
Reduced
Closed
Calls
$8K
Puts
Net Calls
+$8K
Net Calls Change
+$8K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
26
Rivernorth Capital Management
Florida
$472 +$868 +14,999 New
Walleye Trading
27
Walleye Trading
New York
$444 +$811 +14,000 New
BOCH
28
Blue Owl Capital Holdings
New York
$396 +$724 +12,500 New
AA
29
AQR Arbitrage
Connecticut
$390 +$713 +12,313 New
CCA
30
Cobblestone Capital Advisors
New York
$315 +$579 +10,000 New
WAM
31
Wolverine Asset Management
Illinois
$314 +$575 +9,935 New
Bank of America
32
Bank of America
North Carolina
$3 +$6 +100 New

SLXNW Hedge Fund Activity: Q3 2024 in Review

31 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q3 2024, worth a combined $106K.

Buyers outnumbered sellers: 31 funds opened new SLXNW positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $43K.

  • 31 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q3 2024, up from 0 in Q2 2024.
  • Funds reported $106K of Silexion Therapeutics Warrant stock for Q3 2024.
  • 31 funds opened new Silexion Therapeutics Warrant positions in Q3 2024 and 0 closed out, a net change of +31 holders.
  • The largest Silexion Therapeutics Warrant buyer in Q3 2024 was Polar Asset Management Partners, an estimated $43K added.

Based on aggregated 13F filings for Q3 2024.